halcinonide
Trade name: halog
Approved
Nov 27, 1974
Halcinonide is one of the available highly potent topical cor¬ticosteroids. It is a derivative of hydrocortisone and contains important modifications in its structure that alter its absorption, potency, and adverse effects compared with hydrocortisone. Halcinonide—along with desoximetasone, betamethasone, fluocinonide, and diflorasone diacetate—is classified as a Class II potency corticosteroid. Although similar in strength, halcinonide in Halog (the only topical product available that contains halcinonide) differs from many other compounds of this class in the formulation. Halcinonide cream is formulated in a biphasic base that allows for immediate-release of halcinonide upon application to the skin, followed by a delayed and sustained release of halcinonide over time. This “dual formulation” strategy allows for prolonged halcinonide activity. The formulation of halcinonide cream contains microcrystals of halcinonide. An equilibrium is established between dissolved halcinonide in the cream and non-dissolved halcinonide in the microcrystals. As soluble hal¬cinonide enters the skin, additional quantities of halcinonide from the microcrystals become available as a new equilibrium is established. This dynamic equilibrium serves to maintain a sustained level of halcinonide well beyond the time of application. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 7 marketing orgs
Timeline
1970s
- Nov 27, 1974
Sun Pharmaceuticals — Earliest FDA Approval
- Nov 27, 1974
Sun Pharmaceuticals — NDA Secondary Org
- Nov 27, 1974
Sun Pharmaceuticals — NDA Organization
- Jun 15, 1977
Squibb — NDA Secondary Org
2010s
- Aug 12, 2019
Mylan — Marketing Organization
2020s
- Sep 8, 2021
Glasshouse Pharmaceuticals — Marketing Organization
- Sep 8, 2021
Chartwell Pharmaceuticals — Marketing Organization
- May 29, 2024
Encube Ethicals Pvt. Ltd. — Marketing Organization
Indications
Approved for
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Approval history
- approvedNov 27, 1974
Chemistry & pharmacology
SMILES
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl- Mol. weight
- 454.959 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaHalcinonide ↗
- NCATSSI86V6QNEG ↗
- ChEMBLCHEMBL1200845 ↗
Also known as
- (4as,4br,5s,6as,6bs,9ar,10as,10bs)-6b-(chloroacetyl)-4b-fluoro-5-hydroxy-4a,6a,8,8-tetramethyl-3,4,4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-tetradecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
- (4as,4br,5s,6as,6bs,9ar,10as,10bs)-6b-(chloroacetyl)-4b-fluoro-5-hydroxy-4a,6a,8,8-tetramethyl-3,4,4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-tetradecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
- alcinonide
- halciderm
- halcimat
- halcinonid
- halcinonid
- halcinonida
- halcinonida
- halcinonide
- halcinonide
- halcinonide
- halcinonide
- halcinonide
- halcinonide
- halcinonide
- halcinonide
- halcinonide
- halcinonide
- halcinonidum
- halcinonidum
- halog
- halog
- halog
- halog
- halog-e
- halog-e
- so-18566
- so-18566
- sq-18566
- sq-18566
Organizations
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bristol-Myers Squibb | For profit | NDA2 | — |
| Chartwell Pharmaceuticals | For profit | MKTG | Sep 8, 2021 |
| Encube Ethicals Pvt. Ltd. | For profit | MKTG | May 29, 2024 |
| Glasshouse Pharmaceuticals | For profit | MKTG | Sep 8, 2021 |
| Mylan | For profit | MKTG | Aug 12, 2019 |
| Squibb | For profit | NDA2 | Jun 15, 1977 |
| Sun Pharmaceuticals | For profit | NDA2 | Nov 27, 1974 |
| Sun Pharmaceuticals | For profit | NDA | Nov 27, 1974 |